Comparative Pharmacology
Head-to-head clinical analysis: ERYTHRO STATIN versus R P MYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHRO STATIN versus R P MYCIN.
ERYTHRO-STATIN vs R-P MYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythro-statin is a combination of erythromycin, a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, and a statin (HMG-CoA reductase inhibitor) that inhibits cholesterol synthesis. Synergistic effects on inflammation and atherosclerosis are hypothesized.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
200 mg intravenously once daily.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
None Documented
None Documented
2.0-3.5 hours in adults with normal renal function. Extended to 5-8 hours in patients with severe renal impairment (CrCl <30 mL/min).
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Approximately 70-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. About 20-30% is eliminated unchanged in feces via biliary secretion.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic